Fundus Albipunctatus: Symptoms, Causes, and Diagnosis

Fundus albipunctatus is a rare inherited eye condition defined by night blindness and hundreds of small white-yellow dots scattered across the retina. It belongs to a family of disorders called congenital stationary night blindnesses, meaning most people are born with the condition and it typically does not worsen over a lifetime. The reality, though, is more nuanced than that “stationary” label suggests, and how the condition is diagnosed, what causes it at a molecular level, and what it means for long-term vision all deserve a closer look.

What Fundus Albipunctatus Looks Like in the Eye

The hallmark finding is a carpet of tiny, round, white-to-yellowish dots covering the retina. A doctor looking through a dilated pupil will see these spots concentrated most densely in the mid-periphery of the retina, the zone between the central macula and the far edges. The macula itself is usually spared early on, which is why daytime vision stays sharp for most people with the condition.

When imaged with optical coherence tomography (OCT), the dots correspond to bright, reflective deposits sitting between the retinal pigment epithelium (RPE) and the outer segments of the photoreceptor cells. In one study of Chinese families, these hyper-reflective lesions extended from the RPE all the way to the external limiting membrane, suggesting the deposits occupy space that photoreceptors normally use.¹ Adaptive optics imaging, which can resolve individual cells, has confirmed that the spots block the view of both photoreceptors and underlying RPE cells at each lesion site.²

A newer imaging sign, dubbed the “target sign,” appears on near-infrared photography as small circular features that correspond one-to-one with the yellow dots seen clinically and with the bright lines on OCT. In one multi-ethnic cohort, every eye examined showed this target sign, making it a potentially useful diagnostic marker.³

The Symptoms People Actually Notice

Night blindness is the primary complaint and often the reason someone seeks medical attention. People with fundus albipunctatus struggle in dim lighting: driving at dusk, walking through a dark parking garage, or moving around a dimly lit restaurant all become difficult. The condition is present from birth, so young children may not realize their night vision is abnormal until they are old enough to compare their experience with peers. In one reported case, a six-year-old girl was brought in after her parents noticed she had trouble in low light.⁴

Daytime vision is typically unaffected, at least early in life. Color vision and visual acuity under normal lighting conditions remain normal in most patients. This is an important distinction from other retinal dystrophies that chip away at central or color vision from the outset. The white dots themselves are painless and invisible to the patient; they are discovered only when a doctor examines the retina.

What makes this condition unusual among night-blindness disorders is that the rods (the photoreceptor cells responsible for dim-light vision) are not permanently broken. Given enough time in total darkness, rod sensitivity can creep back to near-normal levels. The catch is that “enough time” means roughly two hours or more, compared to about half an hour for someone with typical vision.⁵ In practical terms, this recovery is irrelevant for everyday life, since no one sits in pitch darkness for two hours before needing to see. But it is a crucial clinical clue that separates fundus albipunctatus from conditions where the rods never recover at all.

Why the Visual Cycle Slows Down

The underlying problem is a bottleneck in the biochemical recycling system that regenerates the light-sensitive pigment in your retina. Every time a rod cell absorbs a photon of light, a molecule called 11-cis retinal changes shape and triggers a nerve signal. The spent molecule then needs to be converted back to its original form so the rod can detect the next photon. This recycling happens through a series of chemical steps shared between the photoreceptor cells and the RPE layer beneath them.

In fundus albipunctatus, the final step of this cycle is impaired. An enzyme called RDH5 normally handles the last conversion, turning 11-cis retinol into the active 11-cis retinal that rods need.⁶ When RDH5 does not work properly, this step slows dramatically. The rods are starved of fresh visual pigment, particularly after exposure to light, which is why adapting to darkness takes so much longer than normal. Backup enzymes like RDH11 and RDH10 can partially compensate, which explains why the rods do eventually recover if you wait long enough.

The white-yellow dots on the retina are thought to be accumulations of intermediate molecules that build up because the recycling pathway is congested. They are essentially chemical traffic jams, visible deposits of retinoid compounds that would normally be processed and cleared.

Genetic Causes

Fundus albipunctatus follows an autosomal recessive inheritance pattern. You need two faulty copies of the responsible gene (one from each parent) to develop the condition. Carriers with just one mutant copy have no symptoms and no visible retinal changes.

The gene involved in the vast majority of cases is RDH5, which encodes the enzyme described above. Dozens of different mutations in RDH5 have been identified across families worldwide. In one study of eight families, eleven distinct RDH5 mutations were found, nine of which had never been reported before.⁷ A study of two consanguineous Pakistani families identified a frameshift deletion that segregated perfectly with the disease: affected members carried two copies, while unaffected parents and siblings carried one.⁸ A separate report documented a novel mutation affecting a highly conserved amino acid in the enzyme’s active site in a sixteen-year-old girl with classic night blindness symptoms.⁹

RDH5 is not the only gene that can produce this picture, however. At least one case has been linked to compound heterozygous mutations in RPE65, a different gene in the same visual cycle pathway, with no mutations found in RDH5 at all. That finding was described as the first reported association between RPE65 mutations and a fundus albipunctatus appearance. Rare cases have also been reported with mutations in RLBP1, a gene encoding another retinoid-binding protein. The takeaway is that while RDH5 accounts for the overwhelming majority of cases, genetic testing occasionally turns up surprises.

How the Diagnosis Is Made

Diagnosis usually starts with the clinical appearance of the retina: the characteristic white dots combined with a history of lifelong night blindness raise immediate suspicion. But confirming the diagnosis and ruling out look-alike conditions requires a few additional steps.

Electroretinography

The most telling functional test is a full-field electroretinogram (ERG), which measures the electrical responses of the retina to flashes of light. In fundus albipunctatus, the standard ERG recorded after the usual 20 to 30 minutes of dark adaptation shows severely reduced rod-driven responses. However, if the test is repeated after prolonged dark adaptation of two hours or more, rod responses normalize or nearly normalize.¹⁰ This recovery pattern is the electrophysiological fingerprint of the disease. Cone-driven responses, which handle bright-light and color vision, are typically normal in younger patients.⁴

Retinal Imaging

OCT gives detailed cross-sectional views of the retina and can reveal the hyper-reflective deposits at the photoreceptor-RPE junction. In some patients, OCT shows apparent elongation and splitting of photoreceptors in areas where they have separated slightly from the RPE, while the inner retinal layers look normal.¹¹ Fundus autofluorescence imaging can show small bright dots in some eyes (found in about 44% of eyes in one cohort), and near-infrared imaging reveals the target sign described earlier.³

Genetic Testing

Molecular confirmation through sequencing of RDH5 (and sometimes RPE65 or RLBP1) is increasingly considered part of a complete workup. It provides a definitive answer, helps predict the likely course of the disease, and is becoming essential for anyone who might be eligible for emerging gene-based treatments.

Telling Fundus Albipunctatus Apart From Retinitis Punctata Albescens

The condition most commonly confused with fundus albipunctatus is retinitis punctata albescens (RPA). Both produce white spots on the retina and cause night blindness, but their long-term trajectories are very different. RPA is progressive: it evolves into generalized retinal atrophy with declining vision over time, including loss of peripheral and eventually central sight.¹² Fundus albipunctatus, by contrast, is generally considered stationary, with night vision that does not meaningfully worsen and daytime vision that usually stays intact.¹³

The prolonged dark-adaptation ERG is one of the best ways to distinguish the two. In fundus albipunctatus, rod responses bounce back after extended darkness. In RPA, they do not, because the photoreceptors are actually degenerating. Genetic testing also helps: RPA is more often linked to mutations in RLBP1, while fundus albipunctatus is dominated by RDH5 mutations, though there is some genetic overlap in the same family. One report described a family in which a mutation in RLBP1 caused typical fundus albipunctatus in some members and progressive RPA in others.¹² This complicates the neat division between the two diagnoses and underscores why genetic testing and long-term follow-up matter.

When Fundus Albipunctatus Is Not So Stationary

The label “stationary” is accurate for many patients but misleading for a subset. Some people with confirmed RDH5 mutations develop macular atrophy, a thinning and breakdown of the central retina, that can cause significant central vision loss. One Israeli patient was noted to have night blindness from early childhood but developed progressive deterioration of central vision starting in adolescence. By age 35, his acuity had dropped to 20/200 in one eye and 20/400 in the other, nearing legal blindness, with macular atrophy visible alongside the classic white spots.¹⁴

A case report of a patient with a novel frameshift mutation in RDH5 also documented severe macular atrophy that was not expected given the “stationary” classification. The authors suggested that particular genotype combinations may be associated with a more progressive form of the disease.¹⁵ Whether macular atrophy develops may depend on the specific mutations involved, a person’s age, and potentially other genetic modifying factors that have not yet been pinned down. A large animal model of RDH5 disease in cats showed similar variability: most animals developed central retinal changes as juveniles, but some did not show changes for years, and the researchers hypothesized that other genetic loci influence how severe the disease becomes.¹⁶

This variability has practical consequences. People diagnosed with fundus albipunctatus should not assume their vision will remain unchanged forever. Periodic monitoring of the macula, including OCT and visual acuity checks, is reasonable even when daytime vision seems fine. ERG testing that shows cone-driven responses beginning to decline can be an early warning sign that the disease is taking a less benign course.¹⁴

How Much Variation Exists Between Patients

Even among people who carry confirmed RDH5 mutations and are clinically diagnosed with fundus albipunctatus, the range of presentations is surprisingly broad. In the eight-family study mentioned earlier, visual acuity was normal in all but one eye of one patient who developed late central vision loss. Most patients showed the typical white-dot pattern, but one patient with confirmed RDH5 mutations had a completely normal-looking fundus with no visible dots at all.⁷ That patient still had night blindness and the characteristic ERG pattern, but the classic retinal appearance was absent. This kind of case can make clinical diagnosis tricky, because the white dots are typically considered the defining feature.

The density and distribution of dots also vary. Some people have spots concentrated tightly in the mid-periphery, while others show dots scattered into the perimacular area closer to the center of vision.¹ Whether dot distribution correlates with specific mutations or predicts prognosis is not yet well established. Researchers suspect it is part of the broader genotype-phenotype puzzle that remains to be fully solved.

Living with the Condition

There is currently no approved treatment that corrects the underlying enzyme deficiency. Management focuses on practical adaptations for impaired night vision. Ensuring good ambient lighting, using a flashlight or smartphone light in dim environments, and avoiding driving in dark or poorly lit conditions are straightforward steps that reduce risk.

Night vision spectacles, which amplify residual light and enhance contrast, have been studied in patients with various forms of night blindness. Those with intact daytime vision and normal visual fields tend to benefit the most, particularly for tasks involving contrast and motion perception.⁵ Since people with fundus albipunctatus typically retain good photopic vision and full visual fields, they fall squarely into the group most likely to find these devices helpful.

Children diagnosed at a young age may need accommodations at school, such as seating near windows or under brighter lighting, and communication with teachers about why the child struggles in dim settings like a darkened classroom for a video presentation. Because the condition is so rare, educators and even some general eye care providers may be unfamiliar with it.

Gene Therapy Research

The existence of well-characterized animal models, particularly a naturally occurring RDH5-deficient cat, has opened a door for gene therapy development. In this cat model, gene augmentation therapy delivered to the retina significantly improved the speed of rod recovery after light exposure, directly addressing the slow dark adaptation that defines the condition.¹⁷ The cat model also recapitulates the macular atrophy seen in some human patients, which makes it useful for testing whether gene therapy can prevent that complication as well.¹⁶

No human clinical trials for RDH5-specific gene therapy have been completed as of early 2025. However, the success of gene therapy for a related retinal dystrophy caused by RPE65 mutations (the drug voretigene neparvovec, approved in 2017) established proof of concept that delivering a working copy of a visual-cycle gene to the RPE can restore function. Because RDH5 operates in the same tissue and the same biochemical pathway, the therapeutic logic carries over, though each gene therapy program must clear its own safety and efficacy hurdles.

For patients and families waiting on these developments, genetic testing is a practical first step. Knowing the exact mutations involved not only confirms the diagnosis and helps predict prognosis but also positions someone to participate in future clinical trials as they open. Genetic counseling can clarify the inheritance pattern and recurrence risk for family members considering having children.